Orforglipron
Obstructive Sleep Apnea Syndrome
Eli Lilly and CompanySmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Obstructive Sleep Apnea Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Adalimumab Innovaderm Research Inc. | Phase 4 | BB |
Melatonin Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Phase 4 | BB |
Liraglutide St Vincent's University Hospital, Ireland | Phase 3 | BB |
Mazdutide Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | B |
Eloralintide Eli Lilly and Company | Phase 3 | B |
View all 16 →
Same molecule, other indications
Orforglipron is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →